Technical Analysis for VERV - Verve Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 2.57% | |
| Bollinger Band Squeeze | Range Contraction | 2.57% | |
| Gapped Up | Strength | 2.57% | |
| 20 DMA Resistance | Bearish | 2.57% | |
| Bollinger Band Squeeze | Range Contraction | 2.57% | |
| Gapped Up | Strength | 2.57% | |
| 20 DMA Resistance | Bearish | 2.73% | |
| Shooting Star Candlestick | Bearish | 2.73% | |
| Bollinger Band Squeeze | Range Contraction | 2.73% | |
| BB Squeeze Started | Range Contraction | 2.73% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | 14 minutes ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| 2x Volume Pace | about 6 hours ago |
| 1.5x Volume Pace | about 6 hours ago |
| 3x Volume Pace | about 6 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Verve Therapeutics, Inc. Description
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.4199 |
| 52 Week Low | 5.84 |
| Average Volume | 1,360,432 |
| 200-Day Moving Average | 12.21 |
| 50-Day Moving Average | 9.38 |
| 20-Day Moving Average | 6.33 |
| 10-Day Moving Average | 6.23 |
| Average True Range | 0.61 |
| RSI (14) | 33.77 |
| ADX | 28.54 |
| +DI | 20.65 |
| -DI | 22.96 |
| Chandelier Exit (Long, 3 ATRs) | 5.59 |
| Chandelier Exit (Short, 3 ATRs) | 7.66 |
| Upper Bollinger Bands | 6.86 |
| Lower Bollinger Band | 5.79 |
| Percent B (%b) | 0.41 |
| BandWidth | 16.93 |
| MACD Line | -0.79 |
| MACD Signal Line | -1.01 |
| MACD Histogram | 0.2211 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.98 | ||||
| Resistance 3 (R3) | 7.03 | 6.82 | 6.86 | ||
| Resistance 2 (R2) | 6.82 | 6.63 | 6.80 | 6.81 | |
| Resistance 1 (R1) | 6.53 | 6.51 | 6.43 | 6.48 | 6.77 |
| Pivot Point | 6.32 | 6.32 | 6.27 | 6.30 | 6.32 |
| Support 1 (S1) | 6.03 | 6.13 | 5.93 | 5.98 | 5.69 |
| Support 2 (S2) | 5.82 | 6.01 | 5.80 | 5.65 | |
| Support 3 (S3) | 5.53 | 5.82 | 5.61 | ||
| Support 4 (S4) | 5.48 |
